» Articles » PMID: 25155590

Culture of the Entire Mouse to Determine Whether Cultivable Borrelia Burgdorferi Persists in Infected Mice Treated with a Five-day Course of Ceftriaxone

Overview
Specialty Pharmacology
Date 2014 Aug 27
PMID 25155590
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Although controversial, it has been suggested that antibiotic treatment of laboratory animals infected with Borrelia burgdorferi often leads to the persistence of residual spirochetes that are claimed to be viable but noncultivable. If viable cells of B. burgdorferi do persist following antibiotic therapy, one possible explanation for the lack of cultivability is that too few organisms persist in any given tissue site that might be sampled and cultured. In this study, we treated SKH (hairless) mice, with B. burgdorferi infection of 3 months' duration, with either ceftriaxone or saline for 5 days and then cultured a suspension extract of nearly the entire mouse using a combined in vivo/in vitro culture method. All of the saline-treated (control) mice were culture positive, compared with none of the antibiotic-treated mice. Our findings further document the effectiveness of antibiotic therapy in eradicating cultivable cells of B. burgdorferi, irrespective of tissue or organ site.

Citing Articles

Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease.

Alruwaili Y, Jacobs M, Hasenkampf N, Tardo A, McDaniel C, Embers M Front Microbiol. 2023; 14:1293300.

PMID: 38075920 PMC: 10703379. DOI: 10.3389/fmicb.2023.1293300.


Lyme disease and the pursuit of a clinical cure.

Adkison H, Embers M Front Med (Lausanne). 2023; 10:1183344.

PMID: 37293310 PMC: 10244525. DOI: 10.3389/fmed.2023.1183344.


Persistent Borrelia burgdorferi Infection after Antibiotic Treatment: Systematic Overview and Appraisal of the Current Evidence from Experimental Animal Models.

Verschoor Y, Vrijlandt A, Spijker R, van Hest R, Ter Hofstede H, van Kempen K Clin Microbiol Rev. 2022; 35(4):e0007422.

PMID: 36222707 PMC: 9769629. DOI: 10.1128/cmr.00074-22.


Generality of Post-Antimicrobial Treatment Persistence of Strains N40 and B31 in Genetically Susceptible and Resistant Mouse Strains.

Hodzic E, Imai D, Escobar E Infect Immun. 2019; 87(10).

PMID: 31308087 PMC: 6759297. DOI: 10.1128/IAI.00442-19.


Critical analysis of a doxycycline treatment trial of rhesus macaques infected with Borrelia burgdorferi.

Wormser G, OConnell S, Pachner A, Schwartz I, Shapiro E, Stanek G Diagn Microbiol Infect Dis. 2018; 92(3):183-188.

PMID: 30017315 PMC: 6173987. DOI: 10.1016/j.diagmicrobio.2018.06.007.


References
1.
Johnson R, Marek N, Kodner C . Infection of Syrian hamsters with Lyme disease spirochetes. J Clin Microbiol. 1984; 20(6):1099-101. PMC: 271525. DOI: 10.1128/jcm.20.6.1099-1101.1984. View

2.
Wormser G, Dattwyler R, Shapiro E, Halperin J, Steere A, Klempner M . The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006; 43(9):1089-134. DOI: 10.1086/508667. View

3.
Johnson R, Kodner C, Jurkovich P, Collins J . Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob Agents Chemother. 1990; 34(11):2133-6. PMC: 172012. DOI: 10.1128/AAC.34.11.2133. View

4.
Barthold S, Hodzic E, Imai D, Feng S, Yang X, Luft B . Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrob Agents Chemother. 2009; 54(2):643-51. PMC: 2812145. DOI: 10.1128/AAC.00788-09. View

5.
Pavia C, Inchiosa Jr M, Wormser G . Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice. Antimicrob Agents Chemother. 2001; 46(1):132-4. PMC: 126994. DOI: 10.1128/AAC.46.1.132-134.2002. View